Original Article
Research Letter
Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease

https://doi.org/10.1016/j.cgh.2021.12.045Get rights and content

Cited by (0)

Conflicts of interest This author discloses the following: Dorry L. Segev reports consulting and speaking honoraria from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallinckrodt, and Thermo Fisher Scientific. The remaining authors disclose no conflicts.

Funding This work was made possible by the generous support of the Ben Dov family. This work was supported by grant numbers F32DK124941 (Boyarsky), T32DK007713 (Alejo) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), K24AI144954 (Segev) from the National Institute of Allergy and Infectious Diseases (NIAID), and by grant gSAN-201C0WW from the Transplantation and Immunology Research Network of the American Society of Transplantation (Werbel). The analyses described here are the responsibility of the authors alone and do not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the United States Government.

a

Authors share co-first authorship.

a

Authors share co-first authorship.

b

Authors share co-senior authorship.

b

Authors share co-senior authorship.

View Abstract